We noticed a significant difference in survivin immunoexpression between the GCB and the non-GCB subtype of DLBCL (p = 0.031), namely survivin positivity was noticed more often in the non-GCB than in the GCB subtype (Table 2). This evidence concerns the gene BIRC5 and diffuse large B-cell lymphoma.